Pluvo | $5,000,000 | (Mar 3, 2026)
Flux(US) | $27,000,000 | (Mar 3, 2026)
Multitude Insights | $10,000,000 | (Mar 3, 2026)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Plurio by Elly Analytics | $3,500,000 | (Mar 3, 2026)
Huper Corporation | $1,500,000 | (Mar 3, 2026)
MeltPlan | $10,000,000 | (Mar 3, 2026)
Inhouse | $5,000,000 | (Mar 3, 2026)
Procode AI | $4,000,000 | (Mar 3, 2026)
Temple | $54,000,000 | (Mar 3, 2026)
SECONDSENSE | $2,000,000 | (Mar 3, 2026)
Ease Health | $41,000,000 | (Mar 3, 2026)
Smack Technologies Inc. | $32,000,000 | (Mar 3, 2026)